Wesley Jakubiec

Wesley Jakubiec

Auto-generated profile, based on publicly available information

Wesley Jakubiec

VA Connecticut Healthcare, West Haven, Connecticut, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2010 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
RWRobert S. Wallis
Robert S. Wallis
WJWesley M. Jakubiec
Wesley M. Jakubiec
VKVikas Kumar
Vikas Kumar
ASAnnette M. Silvia
Annette M. Silvia
DPDarcy Paige
Darcy Paige
PMPaul F. Miller
Paul F. Miller
Background. The oxazolidinone PNU-100480 is superior to linezolid against experimental murine tuberculosis. Two metabolites contribute to but do not

18 January 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RWRobert S. Wallis
Robert S. Wallis
WJWesley Jakubiec
Wesley Jakubiec
MMMark Mitton-Fry
Mark Mitton-Fry
LLLynn Ladutko
Lynn Ladutko
SCSheldon Campbell
Sheldon Campbell
PMPaul F. Miller
Paul F. Miller
There presently is no rapid method to assess the bactericidal activity of new regimens for tuberculosis. This study examined PNU-100480, TMC207, PA-824, SQ109, and pyrazinamide, singly and in various combinations, against intracellular M. tuberculosis, using whole blood culture (WBA). The addition of 1,25-dihydroxy vitamin D facilitated detection of the activity of TMC207 in the 3-day cultures. Pyrazinamide failed to show significant activity against a PZA-resistant strain (M. bovis BCG), and was not further considered. Low, mid, and high therapeutic concentrations of each remaining drug were tested individually and in a paired checkerboard fashion. Observed bactericidal activity was compared to that predicted by the sum of the effects of individual drugs. Combinations of PNU-100480, TMC207, and SQ109 were fully additive, whereas those including PA-824 were less than additive or antagonistic. The cumulative activities of 2, 3, and 4 drug combinations were predicted based on the observed concentration-activity relationship, published pharmacokinetic data, and, for PNU-100480, published WBA data after oral dosing. The most active regimens, including PNU-100480, TMC207, and SQ109, were predicted to have cumulative activity comparable to standard TB therapy. Further testing of regimens including these compounds is warranted. Measurement of whole blood bactericidal activity can accelerate the development of novel TB regimens.

17 January 2012 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
VRVenkata M. Reddy
Venkata M. Reddy
TDTia Dubuisson
Tia Dubuisson
LELeo Einck
Leo Einck
RWRobert S. Wallis
Robert S. Wallis
WJWesley Jakubiec
Wesley Jakubiec
CNCarol A. Nacy
Carol A. Nacy
To investigate in vitro interaction between two compounds, SQ109 and PNU-100480, currently in development for the treatment of Mycobacterium tuberculosis (MTB). The two-drug interactions between SQ109 and PNU-100480 and its major metabolite PNU-101603 were assessed by chequerboard titration, and the rate of killing and intracellular activity were determined in both J774A.1 mouse macrophages and whole blood culture. In chequerboard titration, interactions between SQ109 and either oxazolidinone were additive. In time–kill studies, SQ109 killed MTB faster than PNU compounds, and its rate of killing was further enhanced by both oxazolidinones. The order of efficacy of single compounds against intracellular MTB was SQ109 > PNU-100480 > PNU-101603. At sub-MIC, combinations of SQ109 + PNU compounds showed improved intracellular activity over individual drugs; at ≥MIC, the order of efficacy was SQ109 > SQ109 + PNU-100480 > SQ109 + PNU-101603. In whole blood culture, the combined bactericidal activities of SQ109 and PNU-100480 and its major metabolite against intracellular M. tuberculosis did not differ significantly from the sum of the compounds tested individually. SQ109 and PNU combinations were additive and improved the rate of MTB killing over individual drugs. These data suggest that the drugs may work together cooperatively to eliminate MTB in vivo.

1 June 2014 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
APAlberto E. Paniz‐Mondolfi
Alberto E. Paniz‐Mondolfi
LLLynn Ladutko
Lynn Ladutko
BBBarbara A. Brown-Elliott
Barbara A. Brown-Elliott
RVRavikiran Vasireddy
Ravikiran Vasireddy
SVSruthi Vasireddy
Sruthi Vasireddy
SCSheldon Campbell
Sheldon Campbell
Mycobacterium canariasense is a recently described late-pigmenting, rapidly growing mycobacterium linked to bacteremia in patients with underlying malignant diseases. We report a case of M. canariasense infection in a patient from Massachusetts with underlying diffuse B cell lymphoma, which was identified both by multilocus sequence typing and matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS). To our knowledge, this is the first description after its original identification in Spain and the first report of this opportunistic pathogen in the Americas.